Clearside Biomedical Inc CLSD

$0.41 -0.15 (-26.96%)

Valuation

Market cap
2,146,000
Revenue TTM
$1,660,000
Net income TTM
$-34,350,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-2,069.28%
Debt to equity
0.00

Trading

Volume
2,768,700
Avg volume
272,398
Day's range
$0.37 – $0.59
Shares out
5,234,000
Stochastic %K
1%
Beta
2.04
Analysts
Hold
Price target
$59.97

Price

Company profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase...

Show more

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Industry
Biotechnology
Sector
Healthcare
Phone
678 270 3631
Website
https://clearsidebio.com
Address
900 North Point Parkway, Suite 200, Alpharetta, United States

Latest news

No headlines yet.

Stocktwits

SQUEAKSBANDIT Sep 29, 4:54 PM
$OCUL https://stocktwits.com/jbal/message/645174119 $CLSD The ocul call was a bizarre dramatic reading of a script by the ceo and 2 "KOLs" that took a full 45 minutes. They took 3 questions, non-answered them like politicians, and cut it off at 1:05 because of some unknown time constraint, as if they only put one hour on the meter. The presentation was a masterclass of putting lipstick on on a pig. CLS-AX slightly outperformed axpaxli at 24 weeks, in a much harder to treat cohort. CLSD didn't reveal much detail in the ODYSSEY safety profile, but Axpaxli's is a train wreck, as hard the the CEO tries to spin it otherwise. None of this is of any value to CLSD shareholders now as George drove it off a cliff months ago. No new bidders are going to look at the data and palm smack their forehead and realize that the presumption that ocul's insert was a category killer was a fantasy birthed by their CEO. Feb 17, 2026 5:46 PM anyone remember this from feb ?
1 replies
fistedhole Sep 15, 4:08 AM
$CLSD this was one of the first stocks I really invested in. Never really made money. Then called it quits when Covid tanked it. Sad to see where it ended up. Forget was there main thing was? Super cordia micro injections or something. Used to even listen to the calls. Good times being 19 and learning about the market from this one
0 replies
SQUEAKSBANDIT Sep 13, 10:54 PM
$CLSD did the new shares start trading anywhere? has anyone gotten any consideration yet
1 replies
Clifden Aug 17, 1:00 PM
$EYPT We feel your pain $CLSD !! Only cash left went to lawyers and vultures !!
1 replies
PhatTonyC Aug 4, 2:05 PM
$CLSD How long more before we hear exactly how badly fcuked we got?
1 replies
Blancccpain Aug 2, 4:35 PM
$ARBE good question but no any real answer. today i watched a video: why adas cars not ready, where are problem? it was a 5 year old video. worst than that professor at vid. is death . it is highly risky, unready, unavailable tech. arbe just sold oem selection hopium and now they give no hope about that. we ve some deals but u know biotechs, they always burn investors money and i see that some of them go bankcrupcy when their product ready $ADAPY $CLSD i believe positive things are also deals. As if they are not too small, company achieve to not sunking, float level, our price reevaluate with consider possibible future wins btw 2-4 . Some legal things may force oems but it is not suprise for me as if legal codes completely unlinked with 4d radar. if tesla want to maintain its establihment logic, i think they should deal with us. Chinese oem may trigger others
2 replies
SQUEAKSBANDIT Jul 23, 11:56 AM
$CLSD if you'd like, here is the investor contact try calling? Investor Contact: Jennifer Golembeske 212-520-2300 [email protected]
1 replies
JaumeIII Jul 20, 11:39 PM
$CLSD unbelievable that both Thorpe and Lazeskay are still in the board of directors, with Thorpe being the chairman!
0 replies